The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

被引：49

作者：

Holmstrom, M. O. ^{[1
,2
]}

Hjortso, M. D. ^{[2
]}

Ahmad, S. M. ^{[2
]}

Met, O. ^{[2
,3
]}

Martinenaite, E. ^{[2
]}

Riley, C. ^{[1
]}

Straten, P. ^{[2
]}

Svane, I. M. ^{[2
,3
]}

Hasselbalch, H. C. ^{[1
]}

Andersen, M. H. ^{[2
,4
]}

机构：

[1] Zealand Univ Hosp, Dept Hematol, Roskilde, Denmark

[2] Univ Copenhagen, Dept Hematol, Ctr Canc Immune Therapy, Herlev Hosp, Herlev, Denmark

[3] Univ Copenhagen, Dept Oncol, Herlev Hosp, Herlev, Denmark

[4] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark

来源：

LEUKEMIA | 2017年 / 31卷 / 02期

关键词：

POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; DISORDERS; JAK2;

D O I：

10.1038/leu.2016.290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：495 / 498

页数：5

共 15 条

[1] Mechanisms of disease: The myeloproliferative disorders [J].

Campbell, Peter J. ;

Green, Anthony R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2452-2466

[2] Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy [J].

Coulie, Pierre G. ;

Van den Eynde, Benoit J. ;

van der Bruggen, Pierre ;

Boon, Thierry .

NATURE REVIEWS CANCER, 2014, 14 (02) :135-146

[3] Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines [J].

Jedidi, Abire ;

Marty, Caroline ;

Oligo, Charleen ;

Jeanson-Leh, Laurence ;

Ribeil, Jean-Antoine ;

Casadevall, Nicole ;

Galy, Anne ;

Vainchenker, William ;

Villeval, Jean-Luc .

BLOOD, 2009, 114 (09) :1842-1851

[4] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

[5] High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer [J].

Met, Ozcan ;

Balslev, Eva ;

Flyger, Henrik ;

Svane, Inge Marie .

BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (02) :395-406

[6] Response definition criteria for ELISPOT assays revisited [J].

Moodie, Z. ;

Price, L. ;

Gouttefangeas, C. ;

Mander, A. ;

Janetzki, S. ;

Loewer, M. ;

Welters, M. J. P. ;

Ottensmeier, C. ;

van der Burg, S. H. ;

Britten, Cedrik M. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (10) :1489-1501

[7] HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients [J].

Munir, Shamaila ;

Andersen, Gitte Holmen ;

Met, Ozcan ;

Donia, Marco ;

Frosig, Thomas Morch ;

Larsen, Stine Kiaer ;

Klausen, Tobias Wirenfeldt ;

Svane, Inge Marie ;

Andersen, Mads Hald .

CANCER RESEARCH, 2013, 73 (06) :1764-1776

[8] Antitumour actions of interferons: implications for cancer therapy [J].

Parker, Belinda S. ;

Rautela, Jai ;

Hertzog, Paul J. .

NATURE REVIEWS CANCER, 2016, 16 (03) :131-144

[9] JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders [J].

Quentmeier, H ;

Macleod, RAF ;

Zaborski, M ;

Drexler, HG .

LEUKEMIA, 2006, 20 (03) :471-476

[10]

Rammensee H.-G., SYFPEITHI DATABASE M

← 1 2 →